The role of T cells in psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 17, Issue 3, 2003, Pages 257-270

  Prinz, Joerg C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biologic therapy; Cytokine; Immunopathogenesis; Psoriasis; T cell

Indexed keywords

ABX IL 8; ALEFACEPT; AMINOTRANSFERASE; ASCOMYCIN; B7 ANTIGEN; CALCINEURIN; CD28 ANTIGEN; CHEMOKINE; CYCLOSPORIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DENILEUKIN DIFTITOX; EFALIZUMAB; ETANERCEPT; GALIXIMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 4; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD80; PIMECROLIMUS; PSORALEN; RAPAMYCIN; SIPLIZUMAB; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHILL; COLD; COMMON COLD; CYTOKINE RELEASE; DISEASE TRANSMISSION; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXFOLIATIVE DERMATITIS; FATIGUE; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; INFECTION RISK; INJECTION SITE; LEUKOPENIA; LYMPHOCYTIC INFILTRATION; METABOLIC DISORDER; MYCOBACTERIUM VACCAE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; HUMANS; PSORIASIS; PUVA THERAPY; T-LYMPHOCYTES;

EID: 0038025436     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.2003.00720.x     Document Type: Review

References (133)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
2. 389IL-2, for the treatment of psoriasis. Dermatol Ther 1998; 5: 48-63.
3. Barker JNWN. Psoriasis as a T cell-mediated autoimmune disease. Hosp Med 1998; 59: 530-533.
4. Robert C, Kupper TS. Inflammatory skin diseases, T cells and immune surveillance. N Engl J Med 1999; 341: 1817-1828.
5. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol 1996; 110: 199-206.
6. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-1110.
7. Prinz JC. Which T cells cause psoriasis. Clin Exp Dermatol 1999; 24: 291-295.
8. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16: 145-149.
9. Mueller W, Hermann B. Cyclosporin A for psoriasis. N Engl J Med 1976; 301: 355.
10. Griffiths CE, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br Med J 1986; 293: 731-732.
11. Bos JD, Meinardi MM, van Joost T, Heule F, Powles AV, Fry L. Use of cyclosporin in psoriasis. Lancet 1989; 2: 1500-1502.
12. Ellis CN, Fradin MS, Messana JM et al. Cyclosporin for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-284.
13. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. Br Med J 1990; 300: 908.
14. Gardembas-Pain M, Ifrah N, Foussard C, Boasson M, Saint Andre JP, Verrett JL. Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol 1990; 126: 1523.
15. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996; 98: 1878-1887.
16. +) in both normal and diseased human skin. Arch Dermatol Res 1989; 281: 24-30.
17. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and chemokine surface antigen expression indicates an activated, memory/effector type I immunophenotype. Arch Dermatol Res 2000; 292: 519-521.
18. + perivascular dendritic cells. J Invest Dermatol 1991; 96: 333-340.
19. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997; 389: 978-981.
20. Baker S, Swain AF, Valdimarsson H, Fry L. T-cell subpopulation in the blood and skin of patients with psoriasis. Br J Dermatol 1984; 110: 555-564.
21. Braun-Falco O, Christophers E. Structural aspects of initial psoriatic lesions. Arch Dermatol Res 1974; 251: 95-110.
22. Austin L, Ozawa M, Kikuchi T, Walters I, Krueger J. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type I cytokines, IFN-γ, IL-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113: 752-759.
23. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. Invest Dermatol 1995; 105: 89S-94S.
24. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex-vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal stem keratinocytes. J Clin Invest 1995; 95: 317-327.
25. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40-46.
26. Prinz JC, Gross B, Vollmer S et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro. Eur J Immunol 1994; 24: 593-598.
27. Vollmer S, Menessen A, Trommler P, Schendel D, Prinz JC. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 1994; 24: 2377-2382.
28. Abbas AK, Lichtman AH, Pober JS, eds. Cellular and Molecular Immunology, 4th edn. Philadelphia: W.B. Saunders Company, 2000.
29. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000; 343: 37-49.
30. Barnes PJ, Karin M. Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1072.
31. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY, Carter DM. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 1986; 164: 1013-1028.
32. Trembath RC, Clough RL, Rosbotham JL et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997; 6: 813-820.
33. Leung DY, Travers JB, Giorno R et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 1995; 96: 2106-2112.
34. Leung DY, Gately M, Trumble A, Ferguson-Darnell B, Schlievert PM, Picker LJ. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production. J Exp Med 1995; 181: 747-753.
35. Lewis HM, Baker BS, Bokth S et al. Restricted T-cell receptor V beta gene usage in the skin of patients with guttate and chronic plaque psoriasis. Br J Dermatol 1993; 129: 514-520.
36. + T cells in psoriatic lesions preferentially use T-cell receptor Vβ3 and/or Vβ13.1 genes. Proc Natl Acad Sci USA 1994; 91: 9282-9286.
37. Menssen A, Trommler P, Vollmer S et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 1995; 155: 4078-4083.
38. Prinz JC, Vollmer S, Boehncke W-H, Menssen A, Laisney I, Trommler P. Selection of conserved TCR-VDJ-rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur J Immunol 1999; 29: 3360-3368.
39. Tassiulas I, Duncan SR, Centola M et al. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999; 60: 479-491.
40. Vollmer S, Menssen A, Prinz JC. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from non-lesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol 2001; 117: 1296-1301.
41. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr Opin Immunol 1996; 8: 348-354.
42. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
43. Kimber I, Cumberpatch M, Dearman RJ, Bhushan M, Griffiths CEM. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br J Dermatol 2000; 142: 401-412.
44. Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med 2000; 343: 108-117.
45. Novak TJ, Farber D, Leitenberg D, Hong SC, Johnson P, Bottomly K. Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition. Immunity 1994; 1: 109-119.
46. Smyth MJ, Trapani JA. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today 1995; 16: 202-206.
47. Liu CC, Walsh CM, Young JD. Perforin: structure and function. Immunol Today 1995; 16: 194-201.
48. June CH, Fletcher MC, Ledbetter JA, Samelson LE. Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. J Immunol 1990; 144: 1591-1599.
49. Damle NK, Klussman K, Linsley PS, Aruffo A, Ledbetter JA. Differential regulatory effects of intercellular adhesion molecule-1 on costimulation by the CD28 counter-receptor B7. J Immunol 1992; 149: 2541-2548.
50. + T lymphocytes. J Immunol 1992; 148: 1985-1992.
51. Wingren AG, Parra E, Varga M et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995; 15: 235-253.
52. Mueller DL, Jenkins MK, Schwartz RH. An accessory cell-derived costimulatory signal acts independently of protein kinase C activation to allow T cell proliferation and prevent the induction of unresponsiveness. J Immunol 1989; 142: 2617-2628.
53. Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM. T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-483.
54. Sanders ME, Makgoba MW, Sharrow SO et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, Cw29, and Pgp-1) and have enhanced IFN-γproduction. J Immunol 1988; 140: 1401-1407.
55. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66.
56. Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Buck D, Terstapppen LW. Control of lymphocyte recirculation in man I. Differential regulation of the peripheral lymph node homing receptor 1-selectin on T cells during virgin to memory cell transition. J Immunol 1993; 150: 1105-1121.
57. Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Bergstresser PR, Terstapppen LW. Control of lymphocyte recirculation in man II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells. J Immunol 1993; 150: 1122-1136.
58. Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature 1991; 349: 796-799.
59. Homey B, Alenjus H, Müller A et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nature Med 2002; 8: 157-165.
60. von Andrian UH, Mackay CR. T cell function and migration. N Engl J Med 2000; 343: 1020-1034.
61. Groves RW, Ross E, Barker JN, Ross JS, Camp RD, MacDonald DM. Effect of in vivo interleukin-1 on adhesion molecule expression in normal human skin. J Invest Dermatol 1992; 98: 384-387.
62. de Boer OJ, Wakelkamp IM, Pals ST, Claessen N, Bos JD, Das PK. Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. Arch Dermatol Res 1994; 286: 304-311.
63. 2 integrins in vivo. Proc Natl Acad Sci USA 1991; 88: 7538-7542.
64. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 1991; 65: 859-873.
65. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999; 38: 241-251.
66. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101: 701-705.
67. Schlaak JF, Buslau M, Jochum W et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994; 102: 145-149.
68. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
69. Mossman TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146.
70. Rich BE, Kupper TS. Cytokines: IL-20 - a new effector in skin inflammation. Curr Biol 2001; 11: R531-R534.
71. Nickoloff BJ, Wrone-Smith T. Superantigens, autoantigens and pathogenic T cells in psoriasis. J Invest Dermatol 1998; 110: 459-461.
72. + T cells induces psoriasis. Am J Pathol 1999; 155: 145-158.
73. +CTLs as determined by phenotypic analysis. J Cutan Pathol 1998; 25: 79-88.
74. Nicolas JF, Chamchick N, Thivolet J et al. CD4 antibody treatment of severe psoriasis. Lancet 1991; 338: 321.
75. Prinz JC, Braun-Falco O, Meurer M et al. Chimeric CD4 monoclonal antibody in the treatment of generalized pustular psoriasis. Lancet 1991; 338: 320-321.
76. Gottlieb AB, Krueger JG, Bright R et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42: 428-435.
77. Myskowski PL, Ahkami R. Dermatologic complications of HIV infection. Med Clin North Am 1996; 80: 1415-1435.
78. + T cells is independent of cell activation. Cell Adhes Commun 1999; 7: 267-279.
79. Koo J, Lebwohl M. Duration of remission in psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-59.
80. Coven TR, Murphy FP, Gilleaudeau P et al. Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris. Arch Dermatol 1998; 134: 1263-1268.
81. Vallat VP, Gilleaudeau P, Battat L et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994; 180: 283-296.
82. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1995; 1: 442-447.
83. Waters CA, Snider CE, Itoh K et al. DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells. Ann NY Acad Sci 1991; 636: 403-405.
84. 389IL-2 to patients with recalcitrant psoriasis: a double blind, phase II multicenter trial. J Am Acad Dermatol 1998; 38: 938-944.
85. 389IL-2) in patients with severe psoriasis. J Am Acad Dermatol 2001; 45: 871-881.
86. I fusion protein on nonhuman primates. Therap Immunol 1994; 1: 205-216.
87. I fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Therap Immunol 1995; 2: 159-171.
88. Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993; 178: 211-222.
89. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. J Immunol 1994; 152: 2753-2767.
90. Krueger GG. ABX-IL 8 in the treatment of psoriasis: clinical results. 2nd Joint Meeting International Psoriasis Symposium and European Congress on Psoriasis, June 19-24, 2001. Abstract 122.
91. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255.
92. Gottlieb AB, Casale T, Gofe B et al. Impact of a 12-week course of alefacept therapy on primary and secondary immune responses in psoriasis patients. J Eur Acad Dermatol Venereol 2001; 15: 242, Abstract P24-P21.
93. Krueger GG, Papp, KA, Stough DB et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-833.
94. Lebwohl M, Christopher E, Langley R et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol, in press.
95. Branco L, Barren P, Mao S-Y et al. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 1999; 68: 1588-1596.
96. Langley R, Roenigk H, Dingivan C. Safety, tolerance, and disease activity of MEDI-507 for the treatment of moderate to severe psoriasis: a review of phase I results. 2nd Joint Meeting International Psoriasis Symposium and European Congress on Psoriasis June 19-24, 2001. Plenary 7.
97. MedImmune R&D Pipeline. Available at http://www.medimmune.com.
98. Papp K, Bissonnette R, Krueger JG et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665-674.
99. Xanelim in pivotal phase III study shows initial positive results. Study Findings Presented from First of Two Pivotal Phase III Clinical Trials. Genentech press release, June 21, 2001. Available at http://www.gene.com/news/2001/20010621-133134.html.
100. Abrams JR, Kelley SL, Hayes E et al. Blockade of T lymphocyte costimulation with cytoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192: 681-693.
101. Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-1252.
102. Schopf RE. IDEC-114 (IDEC). Curr Opin Invest Drugs 2001; 2: 635-638.
103. IDEC Pharmaceuticals announced results of phase I/II study of IDEC-114 antibody in psoriasis. Press release, March 5, 2001.
104. Carswell CI, Plosker GL, Wagstaff AJ. Daclizumab: a review of its use in the management of organ transplantation. Bio Drugs 2001; 15: 745-773.
105. Krueger JG, Walters IB, Miyazawa M et al. Successful in vivo blockade of CD25 (high-infinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000; 43: 448-458.
106. Finkelman FD. Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease. J Exp Med 1995; 182: 279-282.
107. Asadullah K, Docke WD, Ebeling M et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999; 135: 187-192.
108. Asadullah K, Sterry W, Stephanek K et al. IL-10 is a key cytokine in psoriasis. Clin Invest 1998; 101: 783-794.
109. Trepicchio WL, Ozawa M, Walter IB et al. Interleukin-11 therapy selectively downregulates type 1 cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104: 1527-1537.
110. Ghoreschi R, Thomas P, Breit S, Biedermann T, Prinz J, Sander C, Plewig G, Roecken M. Interleukin 4-induced immune deviation as therapy for psoriasis. J Invest Dermatol 2001; 117: 465, Abstract 453.
111. Kemeny L, Michel G, Dobozy A, Ruzicka T. Cytokine system as potential target for antipsoriatic therapy. Exp Dermatol 1994; 3: 1-8.
112. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829-830.
113. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.
114. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341-1359.
115. Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease. Inflamm Bowel Dis 2001; 7: 327.
116. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344: 1099-1100.
117. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
118. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-390.
119. Alldred A. Etanercept in rheumatoid arthritis. Expert Opin Pharmacother 2001; 2: 1137-1148.
120. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated wih etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 2001; 137: 893-899.
121. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease. A review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5: 119-133.
122. Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13: 16-22.
123. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-2869.
124. Krueger G, Vaishnaw A. The pharmacodynamic effect of alefacept and its correlation to clinical efficacy in chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2001; 15: 251, Abstract P24-P54.
125. Mrowietz U, Graeber M, Brautigam M et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-996.
126. Lehrer A, Bressanelli A, Wachsmann V et al. Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS. Immunol Med Microbiol 1998; 21: 71-77.
127. Balagon MV, Tan PL, Prestidge R et al. Improvement in psoriasis after intradermal administration of delipidated, deglycolipidated Mycobacterium vaccae (PVAC™): results of an open-label trial. Clin Exp Dermatol 2001; 26: 233-241.
128. Paul C, Ho VC. Ascomycins in dermatology. Semin Cutan Med Surg 1998; 17: 256-259.
129. Bornhövd E, Burgdorf WHC, Wollenberg A. Macrolactam immunomodulators to topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001; 45: 736-743.
130. Zuberbier T, Chong S-U, Grunow K et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001; 108: 275-280.
131. Rappersberger K, Komar M, Ebelin ME et al. Oral SDZ 981: safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis. J Invest Dermatol 2000; 114: 776, Abstract.
132. Stanford LJ, Rook GA, Bahr GM et al. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 1990; 8: 525-530.
133. Skinner MA, Yuan S, Prestidge R, Chuk D, Watson JD, Tan PLJ. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun 1997; 65: 4525-4530.